Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,696 | $4,473 | $3,226 | $2,931 |
| - Cash | $1,955 | $2,803 | $1,945 | $2,831 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4,741 | $1,670 | $1,281 | $100 |
| Revenue | $0 | $0 | $0 | $10 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $5 |
| % Margin | – | – | – | 50% |
| EBITDA | -$803 | -$657 | -$534 | -$666 |
| % Margin | – | – | – | -6,660% |
| Net Income | -$803 | -$689 | -$563 | -$790 |
| % Margin | – | – | – | -7,900% |
| EPS Diluted | -0.57 | -0.65 | -0.62 | -0.88 |
| % Growth | 12.3% | -4.8% | 29.5% | – |
| Operating Cash Flow | -$754 | -$680 | -$867 | -$506 |
| Capital Expenditures | -$5 | $0 | $0 | $0 |
| Free Cash Flow | -$759 | -$680 | -$867 | -$506 |